Regeneron Pharmaceuticals, Inc.
REGN
$589.48
-$8.68-1.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.71% | 8.30% | 8.79% | 5.16% | 5.24% |
| Total Other Revenue | -2.24% | -10.61% | -3.94% | 21.45% | 44.06% |
| Total Revenue | 5.38% | 7.52% | 8.27% | 5.72% | 6.46% |
| Cost of Revenue | 13.94% | 13.07% | 13.55% | 10.98% | 12.05% |
| Gross Profit | -2.75% | 2.26% | 3.46% | 1.08% | 1.64% |
| SG&A Expenses | -1.85% | 6.59% | 12.28% | 13.54% | 15.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | 93.90% | 98.13% |
| Total Operating Expenses | 9.20% | 11.15% | 13.20% | 11.83% | 13.84% |
| Operating Income | -3.40% | -0.72% | -2.08% | -6.32% | -7.33% |
| Income Before Tax | 6.27% | 23.31% | 13.83% | 13.55% | -3.94% |
| Income Tax Expenses | 56.76% | 163.25% | 49.49% | -18.27% | -44.27% |
| Earnings from Continuing Operations | 3.17% | 16.63% | 11.61% | 16.62% | 0.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.17% | 16.63% | 11.61% | 16.62% | 0.53% |
| EBIT | -3.40% | -0.72% | -2.08% | -6.32% | -7.33% |
| EBITDA | -1.81% | 0.70% | -0.56% | -4.51% | -5.53% |
| EPS Basic | 3.58% | 15.65% | 10.35% | 15.72% | 0.31% |
| Normalized Basic EPS | 0.81% | 3.20% | 2.39% | -2.26% | -1.61% |
| EPS Diluted | 5.11% | 16.07% | 10.18% | 15.29% | -0.16% |
| Normalized Diluted EPS | 2.16% | 3.57% | 2.26% | -2.66% | -2.08% |
| Average Basic Shares Outstanding | -0.30% | 0.65% | 1.08% | 0.75% | 0.19% |
| Average Diluted Shares Outstanding | -1.73% | 0.09% | 1.19% | 1.14% | 0.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |